Published in
Elsevier, Clinical Lymphoma, Myeloma and Leukemia, (15), p. e50
DOI: 10.1016/j.clml.2015.07.188
Links
Tools
The quadruplet KCRD (carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone) is safe and well tolerated as induction therapy for newly diagnosed, transplant eligible, myeloma patients
Journal article published in 2015 by
C. Pawlyn,
F. Davies,
D. Cairns,
C. Collett,
J. Jones,
M. Kaiser,
A. Chalmers,
A. Striha,
D. Milligan,
J. Lindsay,
C. Chapman,
D. Allotey,
S. Shafeek,
K. Karunanithi 
,
G. Cook
and other authors.
,
G. Cook
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 